• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • AI Executive AssistantNEW
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • AI Executive AssistantNEW
  • Settings
  • RSS Feeds
PublishGo to AppAI Helper
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI employees for your businessNEW
    Legal
    Terms of usePrivacy policyCookie policy

    Baxter Kidney Care is Now Vantive, A New Standalone Vital Organ Therapy Company

    2/3/25 7:00:00 AM ET
    $BAX
    $CG
    Medical/Dental Instruments
    Health Care
    Investment Managers
    Finance
    Get the next $BAX alert in real time by email

    Vantive builds on a 70-year legacy of kidney care leadership and innovation, with a singular focus on empowering patients and care teams with more flexible, collaborative and accessible care options

    With over 1 million daily interactions with patients across more than 100 countries, Vantive exists to extend lives and expand possibilities for patients everywhere

    DEERFIELD, Ill., Feb. 03, 2025 (GLOBE NEWSWIRE) -- Vantive, formerly the Baxter Kidney Care segment, today launched as a new standalone vital organ therapy company following the completion of its acquisition by funds managed by global investment firm Carlyle (NASDAQ:CG) from Baxter International Inc. (NYSE:BAX). Vantive builds on a 70-year legacy as a leader in kidney care innovation to advance its mission of extending lives and expanding possibilities.

    As an independent company, Vantive is dedicated to elevating the standards of kidney and vital organ therapies with a vision to enable longer, fuller lives for patients everywhere. Approximately 4 million people worldwide receive dialysis treatment for chronic kidney disease.1 Access to this life-sustaining treatment varies across regions, and patients on dialysis often face physical and emotional burdens throughout the therapy process. Empowering patients and care teams, while helping to break down the barriers to starting and staying on therapy, is central to Vantive's strategy to advance vital organ therapies.

    "From patients beginning their dialysis journeys to clinicians fighting to save lives in the ICU, accessing the right therapy at the right time is critical. This is why our singular focus as Vantive is to empower more patients and care teams in these moments – with better options, greater control and expanded possibilities," said Chris Toth, CEO of Vantive. "We are beginning a new era of vital organ therapy innovation, and I am looking forward to working with our 23,000 global Vantive colleagues to make a difference for millions of patients and families around the world."

    The Vantive Difference

    Vantive delivers innovative products, digitally-enhanced solutions and advanced services to support dialysis at home and in the clinic, as well as critical care therapy to support the kidney and other vital organs in an intensive care unit (ICU) setting. Patients across more than 100 countries around the world interact with Vantive's people, solutions and services over 1 million times each day. This represents over 1 million opportunities to impact the patient experience every day.

    Through its fully integrated approach to innovation, Vantive seeks to help therapy fit more easily into providers' practices and patients' lives. Vantive's technologies and solutions are designed to elevate the therapy experience, expand efficiencies for care teams, and enhance outcomes for patients. For example, the use of Vantive's remote patient monitoring technology has been associated with lower incidence of all-cause mortality, fewer hospitalizations, reduced treatment drop-out, and greater treatment adherence for home dialysis.2

    "The launch of Vantive represents an important milestone in the continued evolution of kidney care and organ support," said Kieran Gallahue, Chair of the Vantive Board of Directors. "With a clear focus on enabling greater connection, visibility and insights throughout the care journey, Vantive is uniquely positioned to improve the therapy experience for patients and care teams. I am honored to support this dedicated team in advancing Vantive's important mission to extend lives and expand possibilities."

    "We are excited to partner with Vantive to expand the team's global impact and position the business for long-term success," said Robert Schmidt, Carlyle's Global Co-Head of Healthcare. "In this new chapter, Carlyle is committed to supporting Vantive's continued innovation to help enhance care accessibility, quality and outcomes for patients, as well as efficiency for clinicians."

    About Vantive

    Vantive is a vital organ therapy company on a mission to extend lives and expand possibilities for patients and care teams everywhere. For 70 years, our team has driven meaningful innovations in kidney care. Today, patients across more than 100 countries around the world interact with Vantive's people, solutions and services over 1 million times each day. As we build on our legacy, we are deepening our commitment to elevating the dialysis experience through digital solutions and advanced services, while looking beyond kidney care and investing in transforming vital organ therapies. Greater flexibility and efficiency in therapy administration for care teams, and longer, fuller lives for patients— that is what Vantive aspires to deliver. To learn more, visit www.vantive.com and follow us on LinkedIn, X, Facebook, Instagram and YouTube.

    Contact

    Vantive

    Katie Villany

    [email protected]

    ________________________

    1 Jager KJ, Kovesdy C, Langham R, Rosenberg M, Jha V, Zoccali C. A single number for advocacy and communication-worldwide more than 850 million individuals have kidney diseases. Kidney Int. 2019;96(5):1048-1050. doi:10.1016/j.kint.2019.07.012

    2 Paniagua R, Ramos A, Ávila M, et al. Remote monitoring of automated peritoneal dialysis reduces mortality, adverse events, and hospitalizations: a cluster randomized controlled trial. Nephrol Dial Transplant. Published online August 20, 2024. doi:10.1093/ndt/gfae188



    Primary Logo

    Get the next $BAX alert in real time by email

    Crush Q3 2025 with the Best AI Executive Assistant

    Stay ahead of the competition with Tailforce.ai - your AI-powered business intelligence partner.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Tailforce.ai

    Recent Analyst Ratings for
    $BAX
    $CG

    CompanyDatePrice TargetRatingAnalyst
    The Carlyle Group Inc.
    $CG
    7/10/2025$65.00Neutral → Buy
    Citigroup
    The Carlyle Group Inc.
    $CG
    5/14/2025$56.00Hold → Buy
    TD Cowen
    The Carlyle Group Inc.
    $CG
    3/19/2025Outperform → Perform
    Oppenheimer
    Baxter International Inc.
    $BAX
    2/26/2025$42.00Buy
    Goldman
    Baxter International Inc.
    $BAX
    2/24/2025Hold → Buy
    Argus
    Baxter International Inc.
    $BAX
    2/20/2025$39.00Overweight
    Barclays
    The Carlyle Group Inc.
    $CG
    1/3/2025$60.00Peer Perform → Outperform
    Wolfe Research
    The Carlyle Group Inc.
    $CG
    9/12/2024$42.00Equal Weight
    Wells Fargo
    More analyst ratings

    $BAX
    $CG
    Press Releases

    Fastest customizable press release news feed in the world

    See more
    • Baxter Reports Second-Quarter 2025 Results

      Second-quarter sales from continuing operations of $2.81 billion increased 4% on a reported basis and 1% on an operational basis, in line with the company's previously issued guidance1,2 Second-quarter U.S. GAAP3 diluted earnings per share (EPS) from continuing operations of $0.24; adjusted diluted EPS from continuing operations of $0.59, in line with the company's previously issued guidance Recently announced appointment of Andrew Hider as president and chief executive officer (CEO)4 supports company's focus to accelerate innovation, drive sustainable growth, enhance operational effectiveness and create shareholder value Baxter International Inc. (NYSE:BAX), a global medtech lead

      7/31/25 7:15:00 AM ET
      $BAX
      Medical/Dental Instruments
      Health Care
    • Warburg Pincus and Carlyle Announce Agreement to Sell NEOGOV to EQT and CPP Investments

      Sale reflects NEOGOV's industry-leading position in purpose-built government HR and compliance software solutions, providing an essential service to public-sector agencies NEW YORK, July 28, 2025 /PRNewswire/ -- Funds managed by Warburg Pincus LLC, the pioneer of global growth investing, and global investment firm Carlyle (NASDAQ:CG) today announced the signing of a definitive agreement to sell NEOGOV ("the Company"),a provider of HR and compliance software for U.S. public sector agencies, to EQT X fund ("EQT") and Canada Pension Plan Investment Board ("CPP Investments"). Founded in 2000 and headquartered in El Segundo, California, NEOGOV delivers purpose-built human capital management and

      7/28/25 12:23:00 PM ET
      $CG
      Investment Managers
      Finance
    • Carlyle Credit Income Fund Schedules Third Quarter Financial Results and Investor Conference Call

      NEW YORK, July 23, 2025 (GLOBE NEWSWIRE) -- Carlyle Credit Income Fund ("we," "us," "our," "CCIF" or the "Fund") (NYSE:CCIF) announced today that it will release financial results after market close on Tuesday, August 19, 2025, for its third quarter of 2025. CCIF will host a conference call at 10:00 a.m. EST on Wednesday, August 20, 2025, to discuss the results. The conference call will be available via public webcast via a link on Carlyle Credit Income Fund's website at www.carlylecreditincomefund.com and will also be available on the website soon after the call's completion. About Carlyle Credit Income Fund Carlyle Credit Income Fund (NYSE:CCIF) is an externally managed closed-end fun

      7/23/25 4:00:00 PM ET
      $CCIF
      $CG
      Finance/Investors Services
      Finance
      Investment Managers

    $BAX
    $CG
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • SEC Form 4 filed by Large owner Carlyle Group Inc.

      4 - Carlyle Group Inc. (0001527166) (Reporting)

      7/2/25 6:00:04 PM ET
      $CG
      Investment Managers
      Finance
    • EVP and General Counsel Rosenbloom David S. covered exercise/tax liability with 16,548 shares, decreasing direct ownership by 13% to 106,327 units (SEC Form 4)

      4 - BAXTER INTERNATIONAL INC (0000010456) (Issuer)

      6/4/25 4:06:25 PM ET
      $BAX
      Medical/Dental Instruments
      Health Care
    • Large owner Carlyle Group Inc. sold $100,225,698 worth of shares (3,671,271 units at $27.30) (SEC Form 4)

      4 - Carlyle Group Inc. (0001527166) (Reporting)

      6/2/25 4:30:39 PM ET
      $CG
      Investment Managers
      Finance

    $BAX
    $CG
    FDA approvals

    Live FDA approvals issued by the Food and Drug Administration and FDA breaking news

    See more
    • October 18, 2024 - FDA Roundup: October 18, 2024

      For Immediate Release: October 18, 2024 Today, the U.S. Food and Drug Administration is providing an at-a-glance summary of news from around the agency:  This week, FDA continues ongoing efforts to increase access and supply of IV and peritoneal dialysis (PD) fluids following Hurricane Helene-related damage to Baxter International Inc.’s facility in Marion, North Carolina. Specifically, FDA acted quickly to c

      10/18/24 4:16:25 PM ET
      $NVCR
      $BAX
      Medical/Dental Instruments
      Health Care

    $BAX
    $CG
    SEC Filings

    See more
    • Baxter International Inc. filed SEC Form 8-K: Results of Operations and Financial Condition, Financial Statements and Exhibits

      8-K - BAXTER INTERNATIONAL INC (0000010456) (Filer)

      7/31/25 7:18:36 AM ET
      $BAX
      Medical/Dental Instruments
      Health Care
    • The Carlyle Group Inc. filed SEC Form 8-K: Leadership Update, Regulation FD Disclosure, Financial Statements and Exhibits

      8-K - Carlyle Group Inc. (0001527166) (Filer)

      7/28/25 7:06:33 AM ET
      $CG
      Investment Managers
      Finance
    • Baxter International Inc. filed SEC Form 8-K: Leadership Update, Regulation FD Disclosure

      8-K - BAXTER INTERNATIONAL INC (0000010456) (Filer)

      7/7/25 8:51:26 AM ET
      $BAX
      Medical/Dental Instruments
      Health Care

    $BAX
    $CG
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    See more
    • Carlyle Group upgraded by Citigroup with a new price target

      Citigroup upgraded Carlyle Group from Neutral to Buy and set a new price target of $65.00

      7/10/25 8:23:02 AM ET
      $CG
      Investment Managers
      Finance
    • Carlyle Group upgraded by TD Cowen with a new price target

      TD Cowen upgraded Carlyle Group from Hold to Buy and set a new price target of $56.00

      5/14/25 8:48:54 AM ET
      $CG
      Investment Managers
      Finance
    • Carlyle Group downgraded by Oppenheimer

      Oppenheimer downgraded Carlyle Group from Outperform to Perform

      3/19/25 8:14:15 AM ET
      $CG
      Investment Managers
      Finance

    $BAX
    $CG
    Leadership Updates

    Live Leadership Updates

    See more
    • Acentra Health Names Marnie Keogh as Senior Vice President of Marketing

      MCLEAN, Va., July 21, 2025 (GLOBE NEWSWIRE) -- Acentra Health, a technology and health solutions and services company dedicated to accelerating better outcomes for its government and commercial healthcare clients and the populations they serve, announced today that Marnie Keogh has joined the company as Senior Vice President of Marketing. In this role, Keogh will lead the company's integrated marketing strategy, driving initiatives across brand development, digital marketing, thought leadership, and go-to-market campaigns. "Marnie brings a distinguished career in healthcare marketing and communications, with a proven ability to drive brand transformation, operational excellence, and digit

      7/21/25 9:47:00 AM ET
      $CG
      Investment Managers
      Finance
    • SS&C Technologies to Acquire Calastone

      SS&C Technologies Holdings, Inc. (NASDAQ:SSNC) today announced a definitive agreement to acquire Calastone, the largest global funds network and leading provider of technology solutions to the wealth and asset management industries, from global investment firm Carlyle. The purchase price is approximately £766 million (approximately US $1.03 billion), subject to certain adjustments. Headquartered in London, Calastone operates the largest global funds network, connecting more than 4,500 of the world's leading financial organizations across 57 markets. The acquisition is expected to close in Q4 2025, subject to regulatory approvals. SS&C expects the acquisition to be accretive within 12 mont

      7/21/25 4:00:00 AM ET
      $CG
      $SSNC
      Investment Managers
      Finance
      Computer Software: Prepackaged Software
      Technology
    • Baxter Appoints Andrew Hider Chief Executive Officer

      Baxter International Inc. (NYSE:BAX), a global medtech leader, today announced the appointment of Andrew Hider as president and chief executive officer (CEO), and a member of its board of directors. Mr. Hider will assume his responsibilities at Baxter no later than Sept. 3, 2025, or an earlier date pending completion of his current employment commitments. Brent Shafer, who has served as chair and interim CEO since February 2025, will then transition to independent chair of the Baxter Board. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20250706840140/en/Andrew Hider Appointed Baxter's Next CEO Since 2017, Mr. Hider has served as

      7/7/25 8:35:00 AM ET
      $ATS
      $BAX
      Industrial Machinery/Components
      Industrials
      Medical/Dental Instruments
      Health Care

    $BAX
    $CG
    Financials

    Live finance-specific insights

    See more
    • Baxter Reports Second-Quarter 2025 Results

      Second-quarter sales from continuing operations of $2.81 billion increased 4% on a reported basis and 1% on an operational basis, in line with the company's previously issued guidance1,2 Second-quarter U.S. GAAP3 diluted earnings per share (EPS) from continuing operations of $0.24; adjusted diluted EPS from continuing operations of $0.59, in line with the company's previously issued guidance Recently announced appointment of Andrew Hider as president and chief executive officer (CEO)4 supports company's focus to accelerate innovation, drive sustainable growth, enhance operational effectiveness and create shareholder value Baxter International Inc. (NYSE:BAX), a global medtech lead

      7/31/25 7:15:00 AM ET
      $BAX
      Medical/Dental Instruments
      Health Care
    • Carlyle Credit Income Fund Schedules Third Quarter Financial Results and Investor Conference Call

      NEW YORK, July 23, 2025 (GLOBE NEWSWIRE) -- Carlyle Credit Income Fund ("we," "us," "our," "CCIF" or the "Fund") (NYSE:CCIF) announced today that it will release financial results after market close on Tuesday, August 19, 2025, for its third quarter of 2025. CCIF will host a conference call at 10:00 a.m. EST on Wednesday, August 20, 2025, to discuss the results. The conference call will be available via public webcast via a link on Carlyle Credit Income Fund's website at www.carlylecreditincomefund.com and will also be available on the website soon after the call's completion. About Carlyle Credit Income Fund Carlyle Credit Income Fund (NYSE:CCIF) is an externally managed closed-end fun

      7/23/25 4:00:00 PM ET
      $CCIF
      $CG
      Finance/Investors Services
      Finance
      Investment Managers
    • Baxter to Host Second-Quarter 2025 Financial Results Conference Call for Investors

      Baxter International Inc. (NYSE:BAX), a global medtech leader, will host a conference call to discuss its second-quarter 2025 financial results on Thursday, July 31, 2025 at 7:30 a.m. Central Time. To participate in this conference call please follow this link https://registrations.events/direct/Q4I156238 to pre-register for the call and receive the call information. This call is also being webcast and can be accessed through Baxter's website at www.baxter.com. The conference call will be recorded by Baxter and is copyrighted material. It cannot be recorded or rebroadcast without Baxter's permission. About Baxter At Baxter, we are everywhere healthcare happens – and everywhere it is g

      7/17/25 4:15:00 PM ET
      $BAX
      Medical/Dental Instruments
      Health Care

    $BAX
    $CG
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    See more
    • Amendment: SEC Form SC 13D/A filed by The Carlyle Group Inc.

      SC 13D/A - Carlyle Group Inc. (0001527166) (Subject)

      11/15/24 5:22:29 PM ET
      $CG
      Investment Managers
      Finance
    • Amendment: SEC Form SC 13G/A filed by Baxter International Inc.

      SC 13G/A - BAXTER INTERNATIONAL INC (0000010456) (Subject)

      11/13/24 1:08:27 PM ET
      $BAX
      Medical/Dental Instruments
      Health Care
    • Amendment: SEC Form SC 13D/A filed by The Carlyle Group Inc.

      SC 13D/A - Carlyle Group Inc. (0001527166) (Filed by)

      10/21/24 4:31:27 PM ET
      $CG
      Investment Managers
      Finance